Coronary microvascular dysfunction is common in patients hospitalized with COVID-19 infection.

ABSTRACT:

Background and aims

Microvascular disease is considered as one of the main drivers of morbidity and mortality in severe COVID-19, and microvascular dysfunction has been demonstrated in the subcutaneous and sublingual tissues in COVID-19 patients. The presence of coronary microvascular dysfunction (CMD) has also been hypothesized, but direct evidence demonstrating CMD in COVID-19 patients is missing. In the present study, we aimed to investigate CMD in patients hospitalized with COVID-19, and to understand whether there is a relationship between biomarkers of myocardial injury, myocardial strain and inflammation and CMD.

Methods

39 patients that were hospitalized with COVID-19 and 40 control subjects were included to the present study. Biomarkers for myocardial injury, myocar

SUBMITTER: Calıskan M 

PROVIDER: S-EPMC9115225 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature